{"product_id":"predictive-admet-integrated-approaches-in-drug-discovery-and-development-9781118299920","title":"Predictive ADMET Integrated Approaches in Drug","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eBy guiding in the application of techniques and tools for predicting ADMET outcomes in drug candidates,   Predictive ADMET offers a road map for drug discovery scientists to generate effective and safe drugs for unmet medical needs.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“In conclusion, this volume fulfills its promise of being a very useful tool for guidance and diagnosis on ADMET matters, and I would recommend it to any scientist in the field.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 1 June 2015)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface ix\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003eI Introduction to the Current Scientific, Clinical, and Social Environment of Drug Discovery and Development\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Current Social, Clinical, and Scientific Environment of Pharmaceutical R\u0026amp;D 3\u003cbr\u003e\u003ci\u003eLaszlo Urban, Jean-Pierre Valentin, Kenneth I Kaitin, and Jianling Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug-related ADRs 23\u003cbr\u003e\u003ci\u003eTeresa Kaserer, Veronika Temml, and Daniela Schuster\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eII Intelligent Integration and Extrapolation of Admet Data\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3 ADMET Diagnosis Models 49\u003cbr\u003e\u003ci\u003eBernard Faller, Suzanne Skolnik, and Jianling Wang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 PATH (Probe ADME and Test Hypotheses): A Useful Approach Enabling Hypothesis-driven ADME Optimization 63\u003cbr\u003e\u003ci\u003eLeslie Bell, Suzanne Skolnik, and Dallas Bednarczyk\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 PK-MATRIX—A Permeability: Intrinsic Clearance System for Prediction, Classification, and Profiling of Pharmacokinetics and Drug–drug Interactions 89\u003cbr\u003e\u003ci\u003eUrban Fagerholm\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Maximizing the Power of a Local Model for ADMET-property Prediction 103\u003cbr\u003e\u003ci\u003eSebastien Ronseaux, Jeremy Beck, and Clayton Springer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Chemoinformatic and Chemogenomic Approach to ADMET 125\u003cbr\u003e\u003ci\u003eVirginie Y. Martiny, Ilza Pajeva, Michael Wiese, Andrew M. Davis, and Maria A. Miteva\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Multiparameter Optimization of ADMET for Drug Design 145\u003cbr\u003e\u003ci\u003eMatthew D. Segall and Edmund J. Champness\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 PBPK: Integrating In Vitro and In Silico Data in Physiologically Based Models 167\u003cbr\u003e\u003ci\u003eHannah M. Jones and Neil Parrott\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Emerging Full Mechanistic Physiologically Based Modeling 189\u003cbr\u003e\u003ci\u003eKiyohiko Sugano\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Pharmacokinetic\/Pharmacodynamic Modeling in Drug Discovery: A Translational Tool to Optimize Discovery Compounds Toward the Ideal Target-specific Profile 211\u003cbr\u003e\u003ci\u003ePatricia Schroeder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIII Assessment and Mitigation of Critical Clinically Relevant Admet Risks in Drug Discovery and Development\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 In Vitro–In Silico Tools to Predict Pharmacokinetics of Poorly Soluble Drug Compounds 235\u003cbr\u003e\u003ci\u003eChristian Wagner and Jennifer B. Dressman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Evaluation of the Collective Impact of Passive Permeability and Active Transport on In Vivo Blood-brain Barrier and Gastrointestinal Drug Absorption 263\u003cbr\u003e\u003ci\u003eDonna A. Volpe, Hong Shen, and Praveen V. Balimane\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Integrated Assessment of Drug Clearance and Cross-Species Scalability 291\u003cbr\u003e\u003ci\u003eKevin Beaumont, James R. Gosset, and Chris E. Keefer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Practical Anticipation of Human Efficacious Doses and Pharmacokinetics using Preclinical \u003ci\u003eIn Vitro\u003c\/i\u003e and \u003ci\u003eIn Vivo\u003c\/i\u003e Data 319\u003cbr\u003e\u003ci\u003eTycho Heimbach, Rakesh Gollen, and Handan He\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Management and Mitigation of Human Drug–drug Interaction Risks in the Drug Discovery and Development Phases 353\u003cbr\u003e\u003ci\u003eHeidi J. Einolf and Imad Hanna\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Integrated Assessment and Clinical Translation of\u003ci\u003e In Vitro \u003c\/i\u003eOff-target Safety Pharmacology Risks 397\u003cbr\u003e\u003ci\u003ePatrick Y. Muller and Christian F. Trendelenburg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Integrated Risk Assessment of Cardiovascular Safety in Drug Discovery 407\u003cbr\u003e\u003ci\u003eGül Erdemli and Ruth L. Martin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Drug-induced Hepatotoxicity: Advances in Preclinical Predictive Strategies and Tools 433\u003cbr\u003e\u003ci\u003eDonna M. Dambach\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Carcinogenicity and Teratogenicity Assessment 467\u003cbr\u003e\u003ci\u003eHans-Jörg Martus, David Beckman, and Lutz Mueller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Nephrotoxicity: Development of Biomarkers for Preclinical and Clinical Application 491\u003cbr\u003e\u003ci\u003eFrank Dieterle and Estelle Marrer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIV Success Stories and Lessons Learned\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22 Early Intervention with Formulation Strategies for Multidimensional Problems to Optimize for Success 507\u003cbr\u003e\u003ci\u003eStephanie Dodd, Christina Capacci-Daniel, Christopher Towler, Riccardo Panicucci, and Keith Hoffmaster\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Cytochrome P450-mediated Drug Interaction and Cardiovascular Safety: The Seldane to Allegra Transformation 523\u003cbr\u003e\u003ci\u003eF. Peter Guengerich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Clinical Toxicity Profile of VEGF Inhibitors 535\u003cbr\u003e\u003ci\u003eMark P. S. Sie and Ferry A. L. M. Eskens\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Cardiomyopathy: Drug Induced and Predisposed 555\u003cbr\u003e\u003ci\u003eShirley A. Aguirre and Eileen R. Blasi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Safety Management by Pharmacokinetic Considerations: Ranibizumab (Lucentis) and Bevacizumab (Avastin) 569\u003cbr\u003e\u003ci\u003eNicole H. Siegel and Manju L. Subramanian\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 583\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49406848074071,"sku":"9781118299920","price":121.46,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118299920.jpg?v=1730497328","url":"https:\/\/bookcurl.com\/products\/predictive-admet-integrated-approaches-in-drug-discovery-and-development-9781118299920","provider":"Book Curl","version":"1.0","type":"link"}